A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Myeloablative Conditioning in Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.
A shortened five-day stem cell transplant conditioning regimen maintained safety while showing favorable survival, supporting further investigation.
This pilot single-arm transplantation study evaluated Myeloablative conditioning (MAC) with busulfan, melphalan, and fludarabine (Bu/Mel/Flu) given over 8 days in combination with rabbit antithymocyte globulin (ATG) and ex vivo CD34+-selected allogeneic hematopoietic cell transplantation (allo-HCT) leads to favorable disease control and consistently low rates of graft-versus-host d. The authors report that the condensed 5-day regimen was associated with a comparable toxicity profile to the prior sequential 8-day regimen and with favorable survival outcomes supporting further study of this MAC regimen in the context of ex vivo CD34+ selection.
What the study was
- Study design
- Pilot single-arm transplantation study
- Sample size
- 30
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Transplantation and cellular therapy
Why it surfaced
7/10: Pilot single-arm transplantation study with direct relevance to Hematologic malignancies; scoring remains conservative because triage used the PubMed abstract without full-text review.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.